Erdafitinib raw powder is a broad-spectrum FGFR tyrosine kinase small molecule inhibitor. It targets four receptor kinase domains: FGFR1, FGFR2, FGFR3 and FGFR4. The compound suppresses kinase autophosphorylation, so downstream pro-proliferative signals cannot pass on.
If tumor cells have FGFR-related genetic changes, like point mutations, gene amplification or gene fusion, the FGFR pathway keeps turning on nonstop. This drives tumor cells to multiply and invade surrounding tissues. Once erdafitinib binds to these receptors, it can cut off such abnormal signals, reduce tumor cell viability and stop tumors from growing.
It does not only act on FGFR family proteins. It also hits other kinases including RET, PDGFRA, PDGFRB and VEGFR2. These additional inhibitory effects on unrelated kinases are part of why this material causes certain side effects. When erdafitinib gets into cells, it accumulates in lysosomes and releases slowly. This feature helps block FGFR signaling for an extended period and lengthen its action time.
The FGFR pathway takes part in phosphate metabolism inside human bodies. Blocking FGFR with erdafitinib may push up serum phosphate levels. This is a well-known pharmacological property of erdafitinib, and trial teams need to closely track this parameter during studies.
Faithful Chemical offers the products mentioned above. We are committed to providing high-quality service and ensuring that our products are of excellent quality and compliant with international pharmaceutical standards. You can source products from Faithful Chemical with complete confidence.
Erdafitinib raw powder Description
Erdafitinib raw powder is a targeted tyrosine kinase inhibitor material. This product can only be used for lab research, and it is not a dietary supplement. Do not take it orally or use self-administration by any means.
Its main targets are fibroblast growth factor receptors FGFR1/2/3/4. It falls into pan-FGFR kinase inhibitors. This is the key point that makes it different from most antitumor kinase inhibitors. The powder can bind to the kinase domain of FGFR protein, stop FGFR phosphorylation, and block downstream RAS-MAPK/ERK and PI3K-AKT signaling pathways. Then it suppresses proliferation and survival of tumor cells with FGFR activating mutations, amplification or gene fusion. Apart from FGFR family, it also has some inhibition effect on kinases like RET, KIT, VEGFR2. These bring extra pharmacological effects. That is why its cellular action features are quite different from single-target inhibitors.
The efficacy of Erdafitinib raw powder has close connection with dosage. In cell and animal experiments, high or low dose will change FGFR pathway inhibition level and toxicity. Wrong administration may lead to side effects such as hyperphosphatemia, oral mucositis, diarrhea, hand-foot skin reactions, taste change, nail damage and increased liver enzymes. If used for a long time, it will keep disturbing phosphorus metabolism and epithelial cell proliferation inside body. It may also cause serious risks including eye injury and electrolyte imbalance. People need to be very careful when handling this material. After stopping use, the inhibited FGFR pathway will recover little by little, tumor proliferation signals may activate again. Some adverse reactions will also change accordingly, so we cannot ignore these risks.
In scientific research work, Erdafitinib raw powder is widely used in in vitro cell tests and xenograft animal models. Researchers use it to study tumor growth regulation caused by FGFR abnormalities, molecular changes of downstream pathways. They also evaluate how FGFR-mutated tumors respond to targeted interventions. Raw material purity directly affects kinase inhibitory activity. Scientific-grade erdafitinib powder from different manufacturers has purity gaps, and such difference can change activity curve and toxicity data obtained from in vitro experiments.
Erdafitinib raw powder owns oral bioavailability and it is lipophilic. It can be absorbed into blood through gastrointestinal tract, and work on FGFR-expressing cells all over the body. But it does not dissolve well in water, low solubility in aqueous solutions. This is one big physicochemical problem during formulation development. This property will affect the in vitro dosing system and in vivo pharmacokinetic performance.
Important notice: The raw materials of this product are only for laboratory scientific research use and are not health supplements. They cannot be used as self medicated drugs. Direct contact or ingestion in non professional environments can pose serious health hazards.
Global Market Description
In cross-border B2B purchasing, buyers working in biotechnology and new drug R&D do not just check whether Erdafitinib raw powder can bind FGFR targets and suppress tumor cell proliferation. They care more about impurity control standards and batch-to-batch stability. This helps to make sure preclinical tumor studies and formulation tests can generate stable, repeatable lab data.
When formulation R&D researchers source Erdafitinib raw powder for tumor pathway study, pharmacology activity assessment, target validation and formulation development, they need to check a full set of core quality indicators besides basic bioactivity. This keeps experiments stable and makes research results trustworthy across many test scenarios. These include cell culture, tumor animal model tests, preclinical compound screening, FGFR target pharmacology assessment and lab formulation optimization.
Up to 2026, the global market of erdafitinib research raw materials will keep growing at a stable pace. Research powder will still be the most widely adopted and reliable form for this research material.In this field, Faithful Chemical possesses solid advantages and deep experience in global material supply.
| Category | Details |
| Market trend up to 2026 | The global market for Erdafitinib raw powder keeps steady growth |
| Available product form | Research-grade powder |
| Advantage of this form | Highly versatile and trusted research-grade option |
| Applicable scenarios | In vitro FGFR receptor binding assays, dosing in tumor-bearing animal models, preclinical oncology pharmacology assessment, lab formulation optimization |
Three Core Driving Forces
Growing Demand For FGFR Signaling Pathway Research
Rising Interest In Preclinical Anti-tumor Research Projects
Wider Adoption Of This Compound For Pharmacology Screening
We utilize mature production workflows and rigorous testing protocols to ensure the high quality of our Erdafitinib raw powder, meeting international pharmaceutical standards.
With competitive pricing and consistent product quality, you can purchase from Faithful Chemical with confidence.
Application Areas of Erdafitinib Raw Powder
It can support in vitro research related to FGFR targets.
It also allows screening of target inhibition activity.
Cell proliferation and apoptosis detection can be carried out with this material.
It fits many different scientific research scenarios.
These include non-clinical in vivo efficacy evaluation using animal models, short-term toxicology pre-tests, and exploration of formulation processes.
Questions Buyers Ask Before Placing A Bulk Order
Conclusion and References
Conclusion
Erdafitinib raw powder acts as a useful tool for preclinical FGFR tumor research, featuring unique pharmacological characteristics and a wide range of laboratory applications. Its experimental performance is greatly influenced by raw material purity, batch consistency and proper operation, which are core factors that cross-border buyers in biotech and new drug R&D focus on. Along with the continuous growth of market demand, research-grade powder stays as the preferred form for relevant non-clinical research work.
Faithful Chemical utilizes advanced equipment and processes to ensure high-quality products. Our Erdafitinib raw powder meets international pharmaceutical standards. Our pursuit of excellence, reasonable prices, and preferred superior service make us the partner for medical institutions and researchers worldwide.
If you require Phenibut powder research or production
Please contact Faithful Chemical Click
Email: allen@faithfulbio.com
WhatsApp: +86 13137770562
References
1.Perera TPS, Jovcheva E, Mevellec L, et al. Discovery and pharmacological characterization of JNJ-42756493 (erdafitinib), a functionally selective small-molecule FGFR family inhibitor. Mol Cancer Ther. 2017;16(6):1010-1020.
2.Karkera JD, Cardona GM, Bell K, et al. Oncogenic characterization and pharmacologic sensitivity of activating FGFR genetic alterations to erdafitinib. Mol Cancer Ther. 2017;16(8):1717-1726.
3.Mo Y. Erdafitinib suppresses pathological retinal angiogenesis via dual targeting of FGFR and VEGFR2 signaling. Sci Rep. 2025;15:36890.
4.Xue Y, Gao S, Gou J, et al. Erdafitinib inhibits the tumorigenicity of MDA-MB-231 triple-negative breast cancer cells by inducing TRIM25/ubiquitin-dependent degradation of FGFR4. Int J Mol Sci. 2024;25(12):6742.
5.Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381(4):338-348.
6.Meng X. Erdafitinib inhibits tumorigenesis of human lung adenocarcinoma A549 by inducing S-phase cell-cycle arrest. Molecules. 2022;27(19):6321.
7.Takeshita A, Ozaki H, Kosugi T, et al. FGFR inhibition induces increased serum phosphate levels via renal phosphate reabsorption. Sci Rep. 2018;8(1):6917.